<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2009-1-15-20</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-36</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ИММУНОМОДУЛЯТОРОВ ИММУНОВАК ВП-4 И ПРОФЕТАЛЬ НА ФУНКЦИОНАЛЬНУЮ АКТИВНОСТЬ МОНОНУКЛЕАРНЫХ ЛЕЙКОЦИТОВ</article-title><trans-title-group xml:lang="en"><trans-title>INFLUENCE OF IMMUNOMODULATING AGENTS IMMUNOVAK VP-4 AND PROFETAL ON FUNCTIONAL ACTIVITY OF MONONUCLEAR LEUKOCYTES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебединская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedinskaya</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">lebedinska@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахматова</surname><given-names>Н. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmatova</surname><given-names>N. K.</given-names></name></name-alternatives><email xlink:type="simple">lebedinska@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лебединская</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lebedinskaya</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">lebedinska@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черешнев</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chereshnev</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">lebedinska@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родионов</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodionov</surname><given-names>S. U.</given-names></name></name-alternatives><email xlink:type="simple">lebedinska@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киселевский</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiselevsky</surname><given-names>M. V.</given-names></name></name-alternatives><email xlink:type="simple">lebedinska@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГУ «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН», Москва</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ГОУ ВПО «Пермская государственная медицинская академия им. академика Е.А. Вагнера» МЗ РФ</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-3"><institution>«Институт иммунологии и физиологии УрО РАН», г. Екатеринбург</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-4"><institution>ГУ «Российский онкологический научный центр им. Н.Н. Блохина», Москва</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>08</day><month>07</month><year>2014</year></pub-date><volume>11</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лебединская Е.А., Ахматова Н.К., Лебединская О.В., Черешнев В.А., Родионов С.Ю., Киселевский М.В., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Лебединская Е.А., Ахматова Н.К., Лебединская О.В., Черешнев В.А., Родионов С.Ю., Киселевский М.В.</copyright-holder><copyright-holder xml:lang="en">Lebedinskaya E.A., Akhmatova N.K., Lebedinskaya O.V., Chereshnev V.A., Rodionov S.U., Kiselevsky M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/36">https://www.mimmun.ru/mimmun/article/view/36</self-uri><abstract><p>Изучена иммуномодулирующая способность препаратов бактериального (вакцина Иммуновак-ВП-4) и эукариотического происхождения (профеталь), основным действующим компонентом которых является человеческий α-фетопротеин. Культивирование мононуклеарных лейкоцитов с иммуномодуляторами способствует увеличению количества клеток, экспрессирующих поверхностные антигены цитотоксических лимфоцитов, натуральных киллеров и натуральных киллеровT-клеток. Оба препарата обладают выраженным противоопухолевым действием in vitro: индуцируют активацию киллерных свойств мононуклеаров периферической крови человека, которые при этом приобретают свойственный им фенотип.</p></abstract><trans-abstract xml:lang="en"><p>Immunomodulating ability of a bacterial preparation (Immunovak VP-4 vaccine), and a compound of eukariotic origin (profetal), the main active component of human α-fetoprotein were under investigation in present study. Culturing of mononuclear leukocytes with the immunomodulatory factors promotes quantitative increase of the cells that express surface antigens specific for cytotoxic lymphocytes, natural killers and natural killer T-cells. Both bio-active preparations possess an expressed anti-cancer effect in vitro, i.e., they induce activation of killing properties of human peripheral blood mononuclear leukocytes, which is accompanied by acquiring their characteristic phenotype.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>иммуномодуляторы – Иммуновак-ВП-4</kwd><kwd>профеталь</kwd><kwd>натуральные киллеры</kwd><kwd>цитотоксическая активность</kwd><kwd>иммунофенотип</kwd></kwd-group><kwd-group xml:lang="en"><kwd>immunomodulators</kwd><kwd>Immunovak-VP-4</kwd><kwd>Profetal</kwd><kwd>natural killers</kwd><kwd>cytotoxic activity</kwd><kwd>immunophenotype</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ахматова Н.К. Изменение функциональной активности дендритных клеток, генерированных из клеток костного мозга мышей, под воздействием иммуномодулятора микробного происхождения//Цитокины и воспаление. -2007. -Т. 6, № 1. -С. 20-24.</mixed-citation><mixed-citation xml:lang="en">Ахматова Н.К. Изменение функциональной активности дендритных клеток, генерированных из клеток костного мозга мышей, под воздействием иммуномодулятора микробного происхождения//Цитокины и воспаление. -2007. -Т. 6, № 1. -С. 20-24.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Давыдов М.И., Нормантович В.А., Киселевский М.В., Волков С.М. Адоптивная иммунотерапия при опухолевых плевритах: клинико-лабораторное исследование//Российский онкологический журнал. -2000. -№ 6. -С. 14-17.</mixed-citation><mixed-citation xml:lang="en">Давыдов М.И., Нормантович В.А., Киселевский М.В., Волков С.М. Адоптивная иммунотерапия при опухолевых плевритах: клинико-лабораторное исследование//Российский онкологический журнал. -2000. -№ 6. -С. 14-17.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Лебединская О.В., Велижева Н.П., Доненко Ф.В., Черешнев В.А., Родионов С.Ю., Ахматова Н.К., Шубина И.Ж., Лебединская Е.А., Киселевский М.В. Влияние препарата профеталь на дифференцировку и функциональную активность мононуклеарных лейкоцитов человека//Клеточные технологии в биологии и медицине. -2006. -№ 2. -С. 108-117.</mixed-citation><mixed-citation xml:lang="en">Лебединская О.В., Велижева Н.П., Доненко Ф.В., Черешнев В.А., Родионов С.Ю., Ахматова Н.К., Шубина И.Ж., Лебединская Е.А., Киселевский М.В. Влияние препарата профеталь на дифференцировку и функциональную активность мононуклеарных лейкоцитов человека//Клеточные технологии в биологии и медицине. -2006. -№ 2. -С. 108-117.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Черешнев В.А., Родионов С.Ю., Черкасов В.А., Малютина Н.Н., Орлов В.А. Альфа-фетопротеин.-Екатеринбург: УрО РАН, 2004. -C. 376.</mixed-citation><mixed-citation xml:lang="en">Черешнев В.А., Родионов С.Ю., Черкасов В.А., Малютина Н.Н., Орлов В.А. Альфа-фетопротеин.-Екатеринбург: УрО РАН, 2004. -C. 376.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Черешнев В.А., Лебединская О.В., Родионов С.Ю., Ахматова Н.К., Шубина И.Ж., Лебединская Е.А., Гаврилова Т.В., Киселевский М.В. Влияние препарата «Профеталь» на функциональную активность мононуклеарных лейкоцитов и дендритных клеток человека//Медицинская иммунология. -2005. -Т. 7, № 5-6. -С. 525-534.</mixed-citation><mixed-citation xml:lang="en">Черешнев В.А., Лебединская О.В., Родионов С.Ю., Ахматова Н.К., Шубина И.Ж., Лебединская Е.А., Гаврилова Т.В., Киселевский М.В. Влияние препарата «Профеталь» на функциональную активность мононуклеарных лейкоцитов и дендритных клеток человека//Медицинская иммунология. -2005. -Т. 7, № 5-6. -С. 525-534.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Arase N., Arase H., Hirano S., Yokosuka T., Sakurai D., Satito T. IgE-mediated activation of NK cells through Fc gamma RIII//J. Immunol. -2003. -Vol. 15, N 6. -P. 3054-3058.</mixed-citation><mixed-citation xml:lang="en">Arase N., Arase H., Hirano S., Yokosuka T., Sakurai D., Satito T. IgE-mediated activation of NK cells through Fc gamma RIII//J. Immunol. -2003. -Vol. 15, N 6. -P. 3054-3058.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bhardwaj N. Harnessing the immune system to treat cancer//J. Clin. Invest. -2007. -Vol. 117, (5). -P. 1130-1136.</mixed-citation><mixed-citation xml:lang="en">Bhardwaj N. Harnessing the immune system to treat cancer//J. Clin. Invest. -2007. -Vol. 117, (5). -P. 1130-1136.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dudich E.I., Dudich E.I., Semenkova L.N., Dudich I.V. et al. Alpha-fetoprotein-induced apoptosis of cancer cells//Bull. Biol. Med. -2000. -Vol. 130, N 12. -P. 1127-1133.</mixed-citation><mixed-citation xml:lang="en">Dudich E.I., Dudich E.I., Semenkova L.N., Dudich I.V. et al. Alpha-fetoprotein-induced apoptosis of cancer cells//Bull. Biol. Med. -2000. -Vol. 130, N 12. -P. 1127-1133.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Foss F.M. Immunologic mechanisms of antitumor activity//Semin. Oncol. -2002. -Vol. 29. -P. 5-11.</mixed-citation><mixed-citation xml:lang="en">Foss F.M. Immunologic mechanisms of antitumor activity//Semin. Oncol. -2002. -Vol. 29. -P. 5-11.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Galandrini R., Tassi I., Mattia G., Lenti L., Picolli M., Frati L., Santoni A. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells//Blood. -2002. -Vol. 15, N 13. -P. 4581-4589.</mixed-citation><mixed-citation xml:lang="en">Galandrini R., Tassi I., Mattia G., Lenti L., Picolli M., Frati L., Santoni A. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells//Blood. -2002. -Vol. 15, N 13. -P. 4581-4589.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hook C., Telyatnikova N., Goodall J., Braud V., Carmichael A., Wills M. Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis//Clin. Exp. Immunol. -2004. -Vol. 138, N 1. -P. 54-60.</mixed-citation><mixed-citation xml:lang="en">Hook C., Telyatnikova N., Goodall J., Braud V., Carmichael A., Wills M. Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis//Clin. Exp. Immunol. -2004. -Vol. 138, N 1. -P. 54-60.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ikeda H., Chamoto K., Tsuji T., Suzuki Y., Wakita D., Takeshima T., Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy//Cancer Sci. -2004. -Vol. 95, N 9. -P. 697-703.</mixed-citation><mixed-citation xml:lang="en">Ikeda H., Chamoto K., Tsuji T., Suzuki Y., Wakita D., Takeshima T., Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy//Cancer Sci. -2004. -Vol. 95, N 9. -P. 697-703.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mullbacher A. Cell-mediated cytotoxicity in recovery from poxvirus infections//Rev. Med. Virol. -2003. -Vol. 13, N 4. -P. 223-232.</mixed-citation><mixed-citation xml:lang="en">Mullbacher A. Cell-mediated cytotoxicity in recovery from poxvirus infections//Rev. Med. Virol. -2003. -Vol. 13, N 4. -P. 223-232.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nakagawa R., Nagafune I., Tazunoki Y. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by а-galactosylceramide in mice//The Journal of Immunology. -2003. -Vol. 166 (11). -P. 6578-6584.</mixed-citation><mixed-citation xml:lang="en">Nakagawa R., Nagafune I., Tazunoki Y. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by а-galactosylceramide in mice//The Journal of Immunology. -2003. -Vol. 166 (11). -P. 6578-6584.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Narazona R., Casado J., Delarosa O., Torre-Cisneros J., Villanueva J., Sanchez B., Galiana M. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatmentnaive HIV-1-seropositive individuals//J. Clin. Immunol. -2002. -Vol. 22, N 3. -P. 176-183.</mixed-citation><mixed-citation xml:lang="en">Narazona R., Casado J., Delarosa O., Torre-Cisneros J., Villanueva J., Sanchez B., Galiana M. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatmentnaive HIV-1-seropositive individuals//J. Clin. Immunol. -2002. -Vol. 22, N 3. -P. 176-183.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pillai A.B., George T.I., Dutt S., Teo P., Strober S. Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation//J. Immunol. -2007. -Vol. 178 (10). -P. 6242-6251.</mixed-citation><mixed-citation xml:lang="en">Pillai A.B., George T.I., Dutt S., Teo P., Strober S. Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation//J. Immunol. -2007. -Vol. 178 (10). -P. 6242-6251.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Taga K., Yamauchi A., Bloom E. Target cell-induced apoptosis in IL-2-activated human natural killer cells//Leuk. Lymphoma. -1999. -Vol. 32, N. 5. -P. 451-458.</mixed-citation><mixed-citation xml:lang="en">Taga K., Yamauchi A., Bloom E. Target cell-induced apoptosis in IL-2-activated human natural killer cells//Leuk. Lymphoma. -1999. -Vol. 32, N. 5. -P. 451-458.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaguchi Y., Ohshita A., Kawabuchi Y., Ohta K., Shimizu K., Minami K., Hihara J. Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strategies//Hum. Cell. -2006. -Vol. 16, N 4. -P. 183-189.</mixed-citation><mixed-citation xml:lang="en">Yamaguchi Y., Ohshita A., Kawabuchi Y., Ohta K., Shimizu K., Minami K., Hihara J. Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strategies//Hum. Cell. -2006. -Vol. 16, N 4. -P. 183-189.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zund G., Ye Q., Hoerstrup S.P. Tissue engineering in cardiovascular surgery: MTT, a rapid and reliable quantitative method to assess the optimal human cell seeding on polymeric meshes//Eur. J. Cardiothorac. Surg. -1999. -Vol. 15, N 4. -P. 519-524.</mixed-citation><mixed-citation xml:lang="en">Zund G., Ye Q., Hoerstrup S.P. Tissue engineering in cardiovascular surgery: MTT, a rapid and reliable quantitative method to assess the optimal human cell seeding on polymeric meshes//Eur. J. Cardiothorac. Surg. -1999. -Vol. 15, N 4. -P. 519-524.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
